Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHT104
- Development stage
- Preclinical
- Lead developer
- Nanjing Miracle Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Parenteral
01
Overview
CHT104 is a preclinical-stage, dual-targeting universal chimeric antigen receptor T-cell (CAR-T) therapy being developed by Nanjing Miracle Biotechnology. Designed as an allogeneic (off-the-shelf) cell therapy, CHT104 utilizes a dual-targeting approach to enhance therapeutic efficacy and overcome potential antigen escape. The specific molecular targets and therapeutic indications for CHT104 have not been publicly disclosed by the developer. The candidate is currently undergoing preclinical evaluation (PCC stage) in China.
- Other names
- CHT 104CHT104CHT-104Dual-target universal CAR-T
Beyond the preview
Go deeper on CHT104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHT104.